Search
Now showing items 1-2 of 2
Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications
(2019-02-18)
This analysis follows our recent study showing that Canadian public reimbursement delays have lengthened from regulatory approval to listing decisions by public drug plans and delayed public access to innovative medicines, ...
Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions : an exploratory study
(2016-12-27)
BACKGROUND: The CADTH Common Drug Review was established in 2002 to prepare national health technology assessment reports to guide listing decisions for 18 participating drug plans. The aim of this study was to compare the ...